Glucagon-like peptide-1 receptor agonists, commonly known as GLP-1 RAs, have recently garnered significant media attention. Initially developed to improve glycemic control in patients with type 2 diabetes, these medications have also proven to be highly effective for weight loss and enhancing cardiovascular health. However, without proper initiation, titration, and support from the care team, they can often be ineffective and unsustainable. Patients can become stuck in therapeutic inertia. I had the pleasure of presenting on this topic with a pharmacy colleague at this year’s ADCES Annual Conference for diabetes care and education specialists. Here’s how we identified and provided solutions…